These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 34536553)

  • 1. COVID-19 vaccine does not alter panel reactive antibody or flow cytometric cross match in kidney transplant candidates.
    Kumar D; Kimball P; Gupta G
    Transpl Immunol; 2021 Dec; 69():101469. PubMed ID: 34536553
    [No Abstract]   [Full Text] [Related]  

  • 2. Non-Invasive Monitoring for Rejection in Kidney Transplant Recipients After SARS-CoV-2 mRNA Vaccination.
    Al Jurdi A; Gassen RB; Borges TJ; Solhjou Z; Hullekes FE; Lape IT; Efe O; Alghamdi A; Patel P; Choi JY; Mohammed MT; Bohan B; Pattanayak V; Rosales I; Cravedi P; Kotton CN; Azzi JR; Riella LV
    Front Immunol; 2022; 13():838985. PubMed ID: 35281011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SARS-CoV-2 messenger RNA vaccine antibody response and reactogenicity in heart and lung transplant recipients.
    Hallett AM; Greenberg RS; Boyarsky BJ; Shah PD; Ou MT; Teles AT; Krach MR; López JI; Werbel WA; Avery RK; Bae S; Tobian AA; Massie AB; Higgins RSD; Garonzik-Wang JM; Segev DL; Bush EL
    J Heart Lung Transplant; 2021 Dec; 40(12):1579-1588. PubMed ID: 34456108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Standardised neutralising antibody assays are needed for evaluating COVID-19 vaccines.
    Wang Y
    EBioMedicine; 2021 Nov; 73():103677. PubMed ID: 34742128
    [No Abstract]   [Full Text] [Related]  

  • 5. Comparison of mRNA-1273 and BNT162b2 SARS-CoV-2 mRNA Vaccine Immunogenicity in Kidney Transplant Recipients.
    Haller MC; Kaiser RA; Langthaler S; Brandstetter C; Apfalter P; Kerschner H; Cejka D
    Transpl Int; 2021; 35():10026. PubMed ID: 35185359
    [No Abstract]   [Full Text] [Related]  

  • 6. Antibody Responses after Two Doses of COVID-19 mRNA Vaccine in Dialysis and Kidney Transplantation Patients Recovered from SARS-CoV-2 Infection.
    Cappuccilli M; Semprini S; Fabbri E; Fantini M; Bruno PF; Spazzoli A; Righini M; Flachi M; La Manna G; Sambri V; Mosconi G
    Medicina (Kaunas); 2022 Jul; 58(7):. PubMed ID: 35888612
    [No Abstract]   [Full Text] [Related]  

  • 7. Antibody Response to SARS-CoV-2 Infection and Vaccination in COVID-19-naïve and Experienced Individuals.
    Uprichard SL; O'Brien A; Evdokimova M; Rowe CL; Joyce C; Hackbart M; Cruz-Pulido YE; Cohen CA; Rock ML; Dye JM; Kuehnert P; Ricks KM; Casper M; Linhart L; Anderson K; Kirk L; Maggiore JA; Herbert AS; Clark NM; Reid GE; Baker SC
    Viruses; 2022 Feb; 14(2):. PubMed ID: 35215962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody Responses After SARS-CoV-2 mRNA Vaccination in Adults With Inflammatory Bowel Disease.
    Melmed GY; Botwin GJ; Sobhani K; Li D; Prostko J; Figueiredo J; Cheng S; Braun J; McGovern DPB
    Ann Intern Med; 2021 Dec; 174(12):1768-1770. PubMed ID: 34633830
    [No Abstract]   [Full Text] [Related]  

  • 9. COVID-19 mRNA booster vaccines elicit strong protection against SARS-CoV-2 Omicron variant in patients with cancer.
    Zeng C; Evans JP; Chakravarthy K; Qu P; Reisinger S; Song NJ; Rubinstein MP; Shields PG; Li Z; Liu SL
    Cancer Cell; 2022 Feb; 40(2):117-119. PubMed ID: 34986328
    [No Abstract]   [Full Text] [Related]  

  • 10. Kinetics of the Antibody Response to Boostering With Three Different Vaccines Against SARS-CoV-2.
    Markewitz R; Juhl D; Pauli D; Görg S; Junker R; Rupp J; Engel S; Steinhagen K; Herbst V; Zapf D; Krüger C; Brockmann C; Leypoldt F; Dargvainiene J; Schomburg B; Sharifzadeh S; Nejad LS; Wandinger KP; Ziemann M
    Front Immunol; 2022; 13():811020. PubMed ID: 35126395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determinants of early antibody responses to COVID-19 mRNA vaccines in a cohort of exposed and naïve healthcare workers.
    Moncunill G; Aguilar R; Ribes M; Ortega N; Rubio R; Salmerón G; Molina MJ; Vidal M; Barrios D; Mitchell RA; Jiménez A; Castellana C; Hernández-Luis P; Rodó P; Méndez S; Llupià A; Puyol L; Rodrigo Melero N; Carolis C; Mayor A; Izquierdo L; Varela P; Trilla A; Vilella A; Barroso S; Angulo A; Engel P; Tortajada M; García-Basteiro AL; Dobaño C
    EBioMedicine; 2022 Jan; 75():103805. PubMed ID: 35032961
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody affinity maturation and cross-variant activity following SARS-CoV-2 mRNA vaccination: Impact of prior exposure and sex.
    Tang J; Grubbs G; Lee Y; Huang C; Ravichandran S; Forgacs D; Golding H; Ross TM; Khurana S
    EBioMedicine; 2021 Dec; 74():103748. PubMed ID: 34902788
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune Response in Moderate to Critical Breakthrough COVID-19 Infection After mRNA Vaccination.
    Paniskaki K; Anft M; Meister TL; Marheinecke C; Pfaender S; Skrzypczyk S; Seibert FS; Thieme CJ; Konik MJ; Dolff S; Anastasiou O; Holzer B; Dittmer U; Queren C; Fricke L; Rohn H; Westhoff TH; Witzke O; Stervbo U; Roch T; Babel N
    Front Immunol; 2022; 13():816220. PubMed ID: 35145522
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative Effectiveness and Antibody Responses to Moderna and Pfizer-BioNTech COVID-19 Vaccines among Hospitalized Veterans - Five Veterans Affairs Medical Centers, United States, February 1-September 30, 2021.
    Bajema KL; Dahl RM; Evener SL; Prill MM; Rodriguez-Barradas MC; Marconi VC; Beenhouwer DO; Holodniy M; Lucero-Obusan C; Brown ST; Tremarelli M; Epperson M; Mills L; Park SH; Rivera-Dominguez G; Morones RG; Ahmadi-Izadi G; Deovic R; Mendoza C; Jeong C; Schrag SJ; Meites E; Hall AJ; Kobayashi M; McMorrow M; Verani JR; Thornburg NJ; Surie D; ; ;
    MMWR Morb Mortal Wkly Rep; 2021 Dec; 70(49):1700-1705. PubMed ID: 34882654
    [TBL] [Abstract][Full Text] [Related]  

  • 15. mRNA-1273 vaccine (Moderna): a better option than BNT162b2 (Pfizer) in kidney transplant recipients and dialysis patients?
    Wijtvliet VPWM; Ariën KK; Abrams S; Couttenye MM; Mestrez F; Mariën J; De Winter BY; Van Damme P; Pipeleers L; Wissing KM; Abramowicz D; Ledeganck KJ
    Nephrol Dial Transplant; 2022 Mar; 37(4):799-803. PubMed ID: 34888697
    [No Abstract]   [Full Text] [Related]  

  • 16. Safety and cross-variant immunogenicity of a three-dose COVID-19 mRNA vaccine regimen in kidney transplant recipients.
    Massa F; Cremoni M; Gérard A; Grabsi H; Rogier L; Blois M; Couzin C; Hassen NB; Rouleau M; Barbosa S; Martinuzzi E; Fayada J; Bernard G; Favre G; Hofman P; Esnault VLM; Czerkinsky C; Seitz-Polski B; Glaichenhaus N; Sicard A
    EBioMedicine; 2021 Nov; 73():103679. PubMed ID: 34763205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Kinetics of COVID-19 Vaccine Response in a Community-Vaccinated Population.
    Tu MK; Chiang SH; Bender RA; Wong DTW; Strom CM
    J Immunol; 2022 Feb; 208(4):819-826. PubMed ID: 35039333
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity and tolerability of COVID-19 messenger RNA vaccines in primary immunodeficiency patients with functional B-cell defects.
    Pham MN; Murugesan K; Banaei N; Pinsky BA; Tang M; Hoyte E; Lewis DB; Gernez Y
    J Allergy Clin Immunol; 2022 Mar; 149(3):907-911.e3. PubMed ID: 34952033
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Breakthrough infections with SARS-CoV-2 omicron despite mRNA vaccine booster dose.
    Kuhlmann C; Mayer CK; Claassen M; Maponga T; Burgers WA; Keeton R; Riou C; Sutherland AD; Suliman T; Shaw ML; Preiser W
    Lancet; 2022 Feb; 399(10325):625-626. PubMed ID: 35063123
    [No Abstract]   [Full Text] [Related]  

  • 20. Differences in IgG Antibody Responses following BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines.
    Montoya JG; Adams AE; Bonetti V; Deng S; Link NA; Pertsch S; Olson K; Li M; Dillon EC; Frosch DL
    Microbiol Spectr; 2021 Dec; 9(3):e0116221. PubMed ID: 34756093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.